Alex Badamchi-Zadeh

Alex Badamchi-Zadeh, PhD, is a seasoned biotech investor and board observer with extensive experience in the healthcare sector. Currently serving as an investor at BioAge Labs and Nimbus Therapeutics, Badamchi-Zadeh also holds key positions as a board observer for companies such as EyeBio and Alchemab Therapeutics, among others. Notably, Badamchi-Zadeh is a member of the Investment Committee at Cancer Research UK and has been instrumental in significant dealmaking within the biotech industry, including a $3 billion acquisition by Merck and a $6 billion acquisition by Takeda. Academic credentials include a BA and MA in Biological Sciences from the University of Oxford, a PhD in Medicine (Immunology) from Imperial College London, and further business education from Harvard Business School.